An 86.2-point operating-margin swing is hard to miss. Jazz Pharmaceuticals went from a negative 65.6% operating margin in the comparable period to a positive 20.5%, with operating income moving from a $686.4 million loss to $248.2 million of profit.
Revenue rose 15.5% to $1.2 billion, net income reached $192.8 million, and cash increased 36.1% to $1.6 billion. At the latest close, Jazz shares were $252.54, down 2.3% on July 31. The comparison shows a sharp change from a very large loss.
The more interesting part is what Jazz is spending while doing it. Research and development rose to $207.5 million in the three months ended June 30, up from $189.9 million, and the company expects those costs to keep rising as zanidatamab, dordaviprone, and earlier-stage programs move through development.
Jazz tied the revenue increase in one product to a specific change in treatment use:
"Zepzelca product sales increased in the three and six months ended June 30, 2026, compared to the same periods in 2025, primarily due to increased sales volumes, reflecting continued adoption in the first-line maintenance ES-SCLC setting following FDA approval of Zepzelca in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs in October 2025 partially offset by a decline in second line use."
10-Q, August 3, 2026
That is growth through volume and adoption, not a vague pricing story. It also contains its own offset: second-line use declined.
The cost base is moving in the opposite direction from the old loss line. Jazz said clinical studies and outside services were the main reason for the R&D increase, primarily because of zanidatamab.
"R&D expenses increased by $17.6 million in the three months ended June 30, 2026, compared to the same period in 2025, driven by an increase in clinical studies and outside services costs, primarily due to higher costs related to zanidatamab."
10-Q, August 3, 2026
The filing's arithmetic is therefore less tidy than the headline turnaround. Revenue is expanding, cash is building, and free-cash-flow margin reached 34.5%. At the same time, the company is paying more to build the next set of products, while diluted shares rose 13.4% to 69.4 million.
Financing helped at the margin too. Net interest expense fell by $10.3 million in the three months ended June 30, as lower interest expense on the Tranche B-2 Dollar Term Loans and higher interest income more than offset lower interest rates. That is a disclosed benefit, but it is not the same thing as stronger product economics.
The broader record makes the reversal look even more abrupt. Jazz’s 2025 annual results showed a negative 10.1% operating margin, after positive margins in 2023 and 2024. The latest reported period is back in positive territory, but the company does not explain every component of the $934.6 million operating-income swing in the receipts provided here.
Jazz’s next quarterly report should give another comparison for operating income, R&D, cash, and product volumes. The unresolved question is how much of this year’s profit recovery comes from recurring product performance, and how much comes from items the company has not broken out here.
Jazz Pharmaceuticals’ August 3, 2026 10-Q does not fully answer how much of the operating-income swing is repeatable product performance.